Treatment Paradigms for Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:

Treatment Paradigms for Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer

CME Available: https://auau.auanet.org/node/39374
Release Date: December, 2023
Expiration Date: December, 2024

LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Describe the importance of individualized treatment decision-making and shared decision-making in the management of intermediate and high-risk NMIBC.
2. Discuss the challenges associated with BCG shortage and its impact on patient care and treatment decisions.
3. Evaluate alternative intravesical therapies for NMIBC, such as chemotherapeutic agents (e.g., mitomycin C, gemcitabine), novel immunotherapies (e.g., intravesical pembrolizumab), and clinical trials.

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from: 
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 
Lantheus Medical Imaging
Merck & Co., Inc.